AZN.UK

11,586

+0.28%↑

AZN.UK

11,586

+0.28%↑

AZN.UK

11,586

+0.28%↑

AZN.UK

11,586

+0.28%↑

AZN.UK

11,586

+0.28%↑

Search

GlaxoSmithKline PLC

Fermé

SecteurSoins de santé

1,420 0.57

Résumé

Variation du prix de l'action

24h

Actuel

Min

1420

Max

1426.5

Chiffres clés

By Trading Economics

Revenu

-126M

1.6B

Ventes

470M

8B

P/E

Moyenne du Secteur

16.916

34.427

BPA

0.465

Rendement du dividende

4.51

Marge bénéficiaire

20.611

Employés

68,629

EBITDA

137M

3.2B

Recommandations

By TipRanks

Recommandations

Neutre

Prévisions sur 12 Mois

+10.52% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

4.51%

2.47%

Prochains Résultats

29 oct. 2025

Date du Prochain Dividende

9 oct. 2025

Date du Prochain Détachement de Dividende

13 nov. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-420M

57B

Ouverture précédente

1419.43

Clôture précédente

1420

Sentiment de l'Actualité

By Acuity

87%

13%

351 / 374 Classement par Healthcare

GlaxoSmithKline PLC Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

30 juil. 2025, 06:50 UTC

Résultats

GSK Upbeat on Guidance After Specialty Medicines Boost Sales

18 juil. 2025, 09:39 UTC

Principaux Mouvements du Marché

GSK Shares Drop After FDA Committee Vote Leaves Cancer-Drug Comeback in Doubt

2 juin 2025, 10:49 UTC

Principaux Mouvements du Marché
Acquisitions, Fusions, Rachats

Theravance Shares Rise Premarket on Sale of Trelegy Royalties

14 mai 2025, 11:01 UTC

Acquisitions, Fusions, Rachats

GSK Buys Liver-Disease Treatment From Boston Pharmaceuticals for Up to $2 Billion - Update

14 mai 2025, 06:39 UTC

Acquisitions, Fusions, Rachats

GSK Buys Liver-Disease Treatment From Boston Pharmaceuticals for Up to $2 Billion

12 mai 2025, 09:36 UTC

Principaux Mouvements du Marché

Global Pharma Stocks Fall as Trump Plans to Cut Drug Prices

30 juil. 2025, 09:08 UTC

Market Talk
Résultats

GSK Results Look Solid, But Benefit From Temporary Effects -- Market Talk

30 juil. 2025, 06:06 UTC

Résultats

Correct: GSK PLC 2Q EPS 35.5p

30 juil. 2025, 06:00 UTC

Résultats

GSK PLC 2Q EPS 35.5p

30 juil. 2025, 06:00 UTC

Résultats

GSK PLC 2Q Pretax Pft GBP1.89B

30 juil. 2025, 06:00 UTC

Résultats

GSK PLC 2Q Net Pft GBP1.44B

30 juil. 2025, 06:00 UTC

Résultats

GSK PLC 2Q Adj EPS 46.5p

30 juil. 2025, 06:00 UTC

Résultats

GSK PLC 2Q Turnover GBP7.99B

30 juil. 2025, 06:00 UTC

Résultats

GSK PLC 2Q Pre-items, Pretax Pft GBP2.5B

30 juil. 2025, 06:00 UTC

Résultats

GSK PLC 2Q Oper Pft GBP2.02B

28 juil. 2025, 10:51 UTC

Market Talk

U.S.-EU Tariff Deal, Earnings Could Keep Pharma Rally Going -- Market Talk

18 juil. 2025, 09:05 UTC

Actions en Tendance

Stocks to Watch Friday: Netflix, Norfolk Southern, Amex -- WSJ

7 juil. 2025, 15:00 UTC

Acquisitions, Fusions, Rachats

GSK Completes Acquisition of Efimosfermin

2 juin 2025, 10:00 UTC

Acquisitions, Fusions, Rachats

Theravance Biopharma Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225M

15 mai 2025, 15:20 UTC

Actualités

New Allegations About Timing of Pfizer Covid Vaccine Passed to House Panel -- WSJ

14 mai 2025, 06:08 UTC

Acquisitions, Fusions, Rachats

GSK PLC to Buy Efimosfermin from Boston Pharmaceuticals

14 mai 2025, 06:03 UTC

Acquisitions, Fusions, Rachats

GSK PLC: Deal Includes Potential Success-Based Milestone Payments of $800M

14 mai 2025, 06:03 UTC

Acquisitions, Fusions, Rachats

GSK PLC to Pay $1.2B Upfront

14 mai 2025, 06:03 UTC

Acquisitions, Fusions, Rachats

GSK to Buy Efimosfermin for up to $2B

14 mai 2025, 06:00 UTC

Acquisitions, Fusions, Rachats

GSK to Buy Efimosfermin

12 mai 2025, 12:07 UTC

Market Talk

Trump's Drug Price Cap Plan Is 'Alarming' for Pharma Sector -- Market Talk

12 mai 2025, 07:20 UTC

Market Talk

Pharma Shares Face Risks From Trump's Pricing Plans -- Market Talk

30 avr. 2025, 08:54 UTC

Market Talk
Résultats

GSK Investors Turn to U.S. Policy Outlook After Solid Results -- Market Talk

30 avr. 2025, 07:49 UTC

Market Talk
Résultats

GSK's Specialty Meds Sustain Growth, Blenrep Comeback Remains Key -- Market Talk

30 avr. 2025, 07:06 UTC

Market Talk
Résultats

GSK Outperforms Expectations Despite RSV Vaccine Setback -- Market Talk

Comparaison

Variation de prix

GlaxoSmithKline PLC prévision

Objectif de Prix

By TipRanks

10.52% hausse

Prévisions sur 12 Mois

Moyen 1,574.92 GBX  10.52%

Haut 2,170 GBX

Bas 1,290 GBX

Basé sur 14 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Neutre

14 ratings

3

Achat

8

Maintien

3

Vente

Sentiment

By Acuity

351 / 374Classement par Soins de santé

Sentiment de l'Actualité

Très Fortes Indications Baissières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos GlaxoSmithKline PLC

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development; two strategic collaborations with Relation to advance therapeutics for fibrotic diseases and osteoarthritis; and multi-target strategic alliance with GSK to develop breakthrough treatments for people afflicted with Parkinson's disease; as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.dom.